Assure (IONM) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 12, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-40785
Entity Registrant Name	ASSURE HOLDINGS CORP.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	82-2726719
Entity Address, State or Province	CO
Entity Address, Address Line One	7887 E. Belleview Ave., Suite 500
Entity Address, City or Town	Denver
Entity Address, Postal Zip Code	80111
City Area Code	720
Local Phone Number	287-3093
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	IONM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,101,598
Entity Central Index Key	0001798270
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 505	$ 905
Accounts receivable, net	12,887	15,143
Other current assets	401	340
Due from MSAs	4,797	5,006
Total current assets	18,590	21,394
Equity method investments	273	310
Fixed assets	66	76
Operating lease right of use asset, net	617	672
Finance lease right of use asset, net	305	382
Intangibles, net	293	390
Goodwill	1,025	1,025
Total assets	21,169	24,249
Current liabilities
Accounts payable and accrued liabilities	3,615	2,919
Current portion of debt	2,620	965
Current portion of lease liability	524	550
Current portion of acquisition liability	306	306
Other current liabilities	136	231
Total current liabilities	7,201	4,971
Lease liability, net of current portion	826	964
Debt, net of current portion	10,429	11,874
Acquisition liability	102	179
Deferred tax liability, net	1,170	796
Total liabilities	19,728	18,784
Commitments and contingencies (Note 8)
SHAREHOLDERS' EQUITY
Common stock: $0.001 par value; 9,000,000 shares authorized; 1,101,098 and 1,051,098 shares issued and outstanding, as of March 31, 2023 and December 31, 2022, respectively	22	21
Additional paid-in capital	50,289	50,000
Accumulated deficit	(48,870)	(44,556)
Total shareholders' equity	1,441	5,465
Total liabilities and shareholders' equity	$ 21,169	$ 24,249

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	9,000,000	9,000,000	180,000,000
Common stock, shares issued	1,101,098	1,051,098
Common stock, shares outstanding	1,101,098	1,051,098

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total revenue	$ 3,552	$ 4,701
Cost of revenues, excluding depreciation and amortization	3,373	3,877
Gross margin	179	824
Operating expenses
General and administrative	3,211	4,241
Sales and marketing	128	252
Depreciation and amortization	184	258
Total operating expenses	3,523	4,751
Loss from operations	(3,344)	(3,927)
Other income (expenses)
Income from equity method investments	25	5
Gain on Paycheck Protection Program loan forgiveness		1,665
Other expense, net	58	38
Accretion expense	(170)	(170)
Interest expense, net	(509)	(407)
Total other expense	(596)	1,131
Loss before income taxes	(3,940)	(2,796)
Income tax (expense) benefit	(374)	337
Net loss	$ (4,314)	$ (2,459)
Loss per share
Basic	$ (4.09)	$ (3.81)
Diluted	$ (4.09)	$ (3.81)
Weighted average number of shares used in per share calculation - basic	1,054,933	645,950
Weighted average number of shares used in per share calculation - diluted	1,054,933	645,950
Technical services
Revenue
Total revenue	$ 1,234	$ 1,396
Professional services
Revenue
Total revenue	1,874	2,473
Other
Revenue
Total revenue	$ 444	$ 832

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (4,314)	$ (2,459)
Adjustments to reconcile net loss to net cash used in operating activities
Income from equity method investments	(25)	(5)
Stock-based compensation	(10)	323
Depreciation and amortization	184	258
Amortization of debt issuance costs	39	40
Provision for stock option fair value		(23)
Gain on Paycheck Protection Program loan		(1,665)
Accretion expense	170	170
Change in operating assets and liabilities
Accounts receivable, net	2,256	1,351
Prepaid expenses	(61)	(248)
Right of use assets	135	80
Accounts payable and accrued liabilities	697	467
Due from MSAs	234	(66)
Lease liability	(244)	(171)
Income taxes	374	(358)
Other assets and liabilities	(95)	(15)
Net cash used in operating activities	(660)	(2,321)
Cash flows from investing activities
Purchase of fixed assets		(26)
Net cash paid for acquisitions	(77)	(51)
Distributions received from equity method investments	37	35
Net cash used in investing activities	(40)	(42)
Cash flows from financing activities
Proceeds from exercise of stock options		4
Proceeds from share issuance, net	300
Net cash provided by financing activities	300	4
Decrease in cash	(400)	(2,359)
Cash at beginning of period	905	4,020
Cash at end of period	505	1,661
Supplemental cash flow information
Interest paid	$ 550	410
Supplemental non-cash flow information
Purchase of equipment with finance leases		$ 79

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Beginning Balances at Dec. 31, 2021	$ 13	$ 43,387	$ (14,444)	$ 28,956
Beginning Balances (in shares) at Dec. 31, 2021	645,943
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		4		4
Exercise of stock options (in shares)	40
Stock-based compensation		323		323
Net loss			(2,459)	(2,459)
Ending Balance at Mar. 31, 2022	$ 13	43,714	(16,903)	26,824
Ending Balance (in shares) at Mar. 31, 2022	645,983
Beginning Balances at Dec. 31, 2021	$ 13	43,387	(14,444)	28,956
Beginning Balances (in shares) at Dec. 31, 2021	645,943
Ending Balance at Dec. 31, 2022	$ 21	50,000	(44,556)	5,465
Ending Balance (in shares) at Dec. 31, 2022	1,051,098
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuance, net	$ 1	299		300
Share issuance, net (in shares)	50,000
Stock-based compensation		(10)		(10)
Net loss			(4,314)	(4,314)
Ending Balance at Mar. 31, 2023	$ 22	$ 50,289	$ (48,870)	$ 1,441
Ending Balance (in shares) at Mar. 31, 2023	1,101,098

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2023
NATURE OF OPERATIONS
NATURE OF OPERATIONS	1. ​ Assure Holdings Corp., through its two indirect wholly-owned subsidiaries, Assure Neuromonitoring, LLC (“Neuromonitoring”) and Assure Networks, LLC (“Networks”) (“Assure” or the “Company”), provides technical and professional intraoperative neuromonitoring (“IONM”) surgical support services for neurosurgery, spine, cardiovascular, orthopedic, ear, nose, and throat, and other surgical procedures that place the nervous system at risk. interoperative neurophysiologists (“INP”) electroencephalographic ( electromyography (“ The Company was originally incorporated in Colorado on November 7, 2016. In conjunction with a reverse merger, the Company was redomiciled in Nevada on May 16, 2017. Neuromonitoring was formed on August 25, 2015 in Colorado and currently has multiple wholly-owned subsidiaries. The Company’s services are sold in the United States, directly through the Company. Networks was formed on November 7, 2016 in Colorado and holds varying ownerships interests in numerous Provider Network Entities (“PEs”), which are professional IONM entities. These entities are accounted for under the equity method of accounting. Additionally, Networks manages other PEs that Networks does not have an ownership interest and charges those PEs a management feels during surgical procedures and to pre-emptively notify the underlying surgeon of any nervous related issues that are identified. The INPs perform their services in the operating room during the surgeries. The INPs are certified by a third-party accreditation agency.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, and majority-owned entities. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. For entities in which management has determined the Company does not have a controlling financial interest but has varying degrees of influence regarding operating policies of that entity, the Company’s investment is accounted for using the equity method of accounting. All significant intercompany balances and transactions have been eliminated in consolidation. Liquidity The Company’s current cash balance and estimated cash from operations for the next 12 months is not sufficient to meet the Company’s working capital needs for the next 12 months. The Company intends to seek equity or debt financing and have implemented significant cost cutting measures to mitigate its going concern. Such financings may include the issuance of shares of common stock, warrants to purchase common stock, convertible debt or other instruments that may dilute our current stockholders. Financing may not be available to us on acceptable terms depending on market conditions at the time we seek financing. however, there is no guarantee when, or if, these funds will be received during 2023. ​ Accounting Policies There have been no changes to the Company’s significant accounting policies or recent accounting pronouncements during the three months ended March 31, 2023, as compared to the significant accounting policies disclosed in the 10-K for the year ended December 31, 2022 as filed on March 31, 2023. On January 1, 2023, the Company adopted Accounting Standards Update No, 2016-13, and its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired, and each subsequent reporting period. The adoption of this standard did not have a material impact to the Company’s 2023 financial statements. Common Stock Reverse Split During March 2023, the Company effectuated a twenty ​ Reclassifications ​ Certain amounts for the three months ended March 31, 2022 have been reclassified to conform to the 2023 presentation. ​

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2023
REVENUE
REVENUE	3. REVENUE The Company disaggregates revenue from contracts with customers by revenue stream as this depicts the nature, amount, timing and uncertainty of its revenue and cash flows as affected by economic factors. Commercial insurance consists of all Neuromonitoring cases whereby a patient has healthcare insurance. Facility billing consists of services related to uninsured or government patients whereby the Company has an agreement with the facility for services for the patient and other contracted agreements with facilities. ​ The Company’s revenue disaggregated by payor is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 ​ ​ ​ Commercial insurance $ 1,796 ​ $ 2,824 Facility billing ​ 1,312 ​ ​ 1,045 Managed service agreements and other ​ 444 ​ ​ 832 Total $ 3,552 ​ $ 4,701 ​ ​ Accounts Receivable A summary of the accounts receivable, net, by revenue stream is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ December 31, ​ 2023 2022 ​ ​ ​ ​ ​ ​ ​ Technical service ​ $ 2,614 $ 3,072 Professional service ​ ​ 10,067 ​ ​ 11,829 Other ​ 206 ​ 242 Total accounts receivable, net ​ $ 12,887 ​ $ 15,143 ​ The concentration of accounts receivable, net, by payor as a percentage of total accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, ​ As of December 31, ​ ​ 2023 2022 ​ ​ ​ ​ ​ Commercial insurance ​ 88 % ​ 84 % Facility billing ​ 8 % ​ 9 % Other ​ 4 % ​ 7 % Total 100 % ​ 100 % ​

LEASES

LEASES	3 Months Ended
	Mar. 31, 2023
LEASES
LEASES	4. LEASES Under ASC 842, Leases Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. As a practical expedient, the Company elected not to separate non-lease components for the corporate office facility (e.g., common-area maintenance costs) from lease components (e.g., fixed payments including rent) and instead to account for each separate lease component and its associated non-lease components as a single lease component. Operating leases The Company leases corporate office facilities under an operating lease which expires October 31, 2025. The incremental borrowing rate for this lease was 10%. Finance leases The Company leases medical equipment under various financing leases with stated interest rates ranging from 5.2% — 13.4% per annum which expire at various dates through 2026. The condensed consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of March 31, 2023 and December 31, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ December 31, ​ ​ 2023 2022 Operating $ 617 $ 672 Finance ​ 305 ​ 382 Total $ 922 $ 1,054 ​ Finance lease assets are reported net of accumulated amortization of $2.5 million and $2.4 million as of March 31, 2023 and December 31, 2022, respectively. ​ The following are the components of lease cost for operating and finance leases (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2023 2022 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ $ 77 ​ $ 77 Interest on lease liabilities ​ ​ 19 ​ ​ 23 Total operating lease cost ​ ​ 96 ​ ​ 100 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 77 ​ ​ 169 Interest on lease liabilities ​ ​ 14 ​ ​ 24 Total finance lease cost ​ ​ 91 ​ ​ 193 Total lease cost ​ $ 187 ​ $ 293 ​ ​ The following are the weighted average lease terms and discount rates for operating and finance leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ ​ March 31, 2023 ​ March 31, 2022 ​ Weighted average remaining lease term (years): ​ ​ ​ ​ ​ Operating leases 2.5 ​ 3.5 ​ Finance leases 1.9 ​ 2.9 ​ Weighted average discount rate (%): ​ ​ ​ ​ ​ Operating leases 5.6 ​ 10.0 ​ Finance leases 9.2 ​ 7.8 ​ ​ Future minimum lease payments and related lease liabilities as of March 31, 2023 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder of 2023 ​ $ 219 ​ $ 247 ​ $ 466 2024 ​ 328 ​ 268 ​ 596 2025 ​ 279 ​ 153 ​ 432 2026 ​ ​ — ​ ​ 23 ​ ​ 23 Total lease payments ​ 826 ​ 691 ​ 1,517 Less: imputed interest ​ (104) ​ (63) ​ (167) Present value of lease liabilities ​ ​ 722 ​ ​ 628 ​ ​ 1,350 Less: current portion of lease liabilities ​ 243 ​ 281 ​ 524 Noncurrent lease liabilities ​ $ 479 ​ $ 347 ​ $ 826 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Note: Future minimum lease payments exclude short-term leases as well as payments to landlords for variable common area maintenance, insurance and real estate taxes.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2023
DEBT
DEBT	5. DEBT The Company’s debt obligations are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2023 2022 Face value of convertible debenture ​ $ 3,450 ​ $ 3,450 Less: principal converted to common shares ​ ​ (60) ​ ​ (60) Less: deemed fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 1,181 ​ ​ 1,086 Total convertible debt ​ 3,048 ​ 2,953 ​ ​ ​ ​ ​ ​ ​ Face value of Centurion debenture ​ ​ 11,000 ​ ​ 11,000 Less: deemed fair value ascribed to warrants ​ ​ (1,204) ​ ​ (1,204) Plus: accretion of implied interest ​ ​ 552 ​ ​ 476 Less: net debt issuance costs ​ ​ (347) ​ ​ (386) Total Centurion debt ​ 10,001 ​ 9,886 Total debt ​ 13,049 ​ 12,839 Less: current portion of debt ​ (2,620) ​ (965) Long-term debt ​ $ 10,429 ​ $ 11,874 ​ ​ ​ The following table depicts accretion expense and interest expense (excluding debt issuance cost amortization) related to the Company’s debt obligations for the three months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Accretion expense ​ ​ Convertible debenture $ 95 ​ $ 95 Centurion debenture 75 ​ ​ 75 ​ $ 170 ​ $ 170 ​ ​ ​ ​ ​ ​ Debt issuance cost amortization ​ ​ Centurion debenture $ 39 ​ $ 40 ​ ​ ​ ​ ​ ​ Interest paid ​ ​ ​ ​ ​ Convertible debenture $ 174 ​ $ 77 Centurion debenture 376 ​ 263 ​ $ 550 ​ $ 340 ​ ​ ​ As of March 31, 2023, future minimum principal payments are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ Debt Debenture 2023 ​ $ 2,560 ​ $ — 2024 ​ 830 ​ — 2025 ​ — ​ 11,000 Total ​ ​ 3,390 ​ ​ 11,000 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,204) Plus: accretion and implied interest ​ 1,181 ​ 552 Less: net debt issuance costs ​ ​ — ​ ​ (347) ​ ​ $ 3,048 ​ $ 10,001 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Paycheck Protection Program ​ During March 2021, the Company received an unsecured loan under the United States Small Business Administration Paycheck Protection Program (“PPP”) in the amount of $1.7 million. Assure executed a PPP promissory note, with an original maturity date of February 25, 2026 (the “PPP Loan”). The PPP Loan carried an interest rate of 1.0% per annum, with principal and interest payments due on the first day of each month, with payments commencing on the earlier of: (i) the day the amount of loan forgiveness granted to Assure was remitted by the Small Business Administration to the Bank of Oklahoma; or (ii) 10 months after the end of the 24-week period following the grant of the PPP Loan. Under the terms of the PPP Loan, all or a portion of the PPP Loan may be forgiven if the Company maintains its employment and compensation within certain parameters during the 24-week period following the loan origination date and the proceeds of the PPP Loan were spent on payroll costs, rent or lease agreements dated before February 15, 2020, and utility payments arising under service agreements dated before February 15, 2020. The Company submitted its application for forgiveness of the PPP Loan during the fourth quarter of 2021 and in January 2022, the Company received forgiveness of the $1.7 million PPP Loan resulting in no balance due. Convertible Debt From November 2019 through May 2020, the Company closed multiple non-brokered private placements of convertible debenture units (“CD Unit”) for gross proceeds of $3.5 million. Each CD Unit was offered at a price of $1. Each CD Unit included, among other things, one common share purchase warrant that allows the holder to purchase shares of the Company’s common stock at prices ranging from $5.00 to $9.50 per share for a period of three years and the right to convert the CD Unit into shares of the Company’s common stock at a conversion prices ranging from $3.35 to $7.00 per share for a period of four years. The CD Units carry a 9% coupon rate. The fair value of the convertible debt was determined to be $1.7 million, the conversion feature $1.2 million and the warrants $600 thousand. The difference between the fair value of the debt of $1.7 million and the face value of convertible debt of $3.5 million is being accreted over the four-year life of the CD Units. Centurion Debt In June 2021, Assure issued a debenture to Centurion (the “Debenture”) with a maturity date of June 9, 2025 (the “Maturity Date”), in the principal amount of $11 million related to a credit facility comprised of a $6 million senior term loan (the “Senior Term Loan”), a $2 million senior revolving loan (the “Senior Revolving Loan”) and a $3 million senior term acquisition line (the “Senior Term Acquisition Line” and together with the Senior Term Loan and the Senior Revolving Loan, the “Credit Facility”). Additionally, the Company issued 13,750 warrants with an exercise price of $7.55 which expire on June 14, 2025. During November 2021, the Company and Centurion entered into an amendment to allow the Senior Short Term Acquisition Line to be utilized for organic growth and general working capital purposes. Under the terms and conditions of the debt arrangement, Centurion modified their debt covenant calculations to allow bad debt expense to be excluded. The Company’s was in compliance with the debt covenants as of March 31, 2023. The Credit Facility matures in June 2025 and bears interest at the rate of the greater of 9.50% or the Royal Bank of Canada Prime Rate plus 7.05% per annum. The fair value of the Debenture was determined to be $6.8 million and the warrants $1.2 million. The difference between the fair value of the debt of $6.8 million and the face value of the Debenture of $8.0 million will be accreted over the four-year term of the Debenture.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Mar. 31, 2023
SHARE CAPITAL
SHARE CAPITAL	6. SHARE CAPITAL Common stock Common stock: 9,000,000 authorized; $0.001 par value. As of March 31, 2023, and December 31, 2022, there were 1,101,098 and 1,051,098 shares of common stock issued outstanding Reverse Share Split ​ During March 2023, the total number of shares of common stock authorized by the Company was reduced from 180,000,000 shares of common stock, par $0.001, to 9,000,000 shares of common stock, par $0.001, and the number of shares of common stock held by each stockholder of the Company were consolidated automatically into the number of shares of common stock equal to the number of issued and outstanding shares of common stock held by each such stockholder immediately prior to the reverse split divided by twenty twenty one ​ No fractional shares were issued in connection with the reverse split and all fractional shares were rounded up to the next whole share. ​ Additionally, all options, warrants and other convertible securities of the Company outstanding immediately prior to the reverse split were adjusted by dividing the number of shares of common stock into which the options, warrants and other convertible securities are exercisable or convertible by twenty twenty ​ All shares of common stock, options, warrants and other convertible securities and the corresponding price per share amounts have been presented to reflect the reverse split in all periods presented within this Form 10-Q. ​ Share Issuance During March 2023, the Company completed a private placement for 50,000 common shares at $6.00 per common shares for gross proceeds of $300 thousand. Stock options On December 10, 2020, shareholders approved amendments to the Company’s stock option plan, which amended the plan previously approved on November 20, 2019 (the “Amended Stock Option Plan”). On December 10, 2020, the Company’s shareholders approved the adoption of a new fixed equity incentive plan (the “ ​ In November 2021, the Company adopted and approved the 2021 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan. The intent of the Company and the Board of Directors is that while the Amended 2020 Stock Option Plan and the 2020 Equity Incentive Plan will continue in existence in relation to the options and awards previously granted, the Board will not grant future options or awards thereunder. Instead, only the 2021 Stock Incentive Plan will be used for the grant of options and awards to eligible participants. ​ As of March 31, 2023, there was 40,940 stock options outstanding under the Amended Stock Option Plan. No additional stock options will be issued under the Amended Stock Option Plan. As of March 31, 2023, there was 4,000 stock options outstanding and an aggregate of 96,000 shares of common stock were available for issuance under the 2021 Stock Option Plan. As of March 31, 2023, no transactions have occurred under the 2021 Employee Stock Purchase Plan. ​ Options under the 2021 Stock Option Plan are granted from time to time at the discretion of the Board of Directors, with vesting periods and other terms as determined by the Board of Directors. ​ A summary of the stock option activity is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2021 60,212 ​ $ 111.20 3.60 ​ Options granted 6,500 ​ $ 103.20 ​ ​ ​ ​ ​ Options exercised (40) ​ $ 100.80 ​ ​ ​ ​ ​ Options canceled / expired (17,632) ​ $ 50.20 ​ ​ ​ ​ ​ Balance at December 31, 2022 49,040 ​ $ 129.60 ​ 2.8 ​ ​ ​ Options canceled / expired (4,100) ​ $ 112.72 ​ ​ ​ ​ ​ Balance at March 31, 2023 44,940 ​ $ 131.09 2.4 $ — Vested and exercisable at March 31, 2023 34,900 ​ $ 134.36 2.2 $ — ​ The following table summarizes information about stock options outstanding and exercisable under the Company’s Stock Option Plan at March 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 750 4.8 ​ $ 180.00 750 ​ $ 180.00 4,200 0.5 ​ $ 180.00 4,200 ​ $ 180.00 7,290 0.8 ​ $ 156.00 7,290 ​ $ 156.00 3,395 1.5 ​ $ 128.00 3,395 ​ $ 128.00 3,900 2.7 ​ $ 97.00 2,860 ​ $ 97.00 12,255 ​ 2.8 ​ $ 106.00 ​ 9,174 ​ $ 106.00 1,500 ​ 3.0 ​ $ 112.00 ​ 900 ​ $ 112.00 7,650 ​ 3.5 ​ $ 153.00 ​ 4,465 ​ $ 153.00 4,000 ​ 3.9 ​ $ 103.20 ​ 1,866 ​ $ 103.20 44,940 2.4 ​ $ 131.09 34,900 ​ $ 134.36 ​ The Company uses the Black-Scholes option pricing model to determine the estimated fair value of options. The fair value of each option grant is determined on the date of grant and the expense is recorded on a straight-line basis and is included as a component of general and administrative expense in the consolidated statements of operations. The assumptions used in the model include expected life, volatility, risk-free interest rate, dividend yield and forfeiture rate. The Company’s determination of these assumptions is outlined below. Expected life — Volatility — Risk-free interest rate — Dividend yield — Forfeiture rate — The following assumptions were used to value the awards granted during the three months ended March 31, 2022: ​ ​ ​ ​ ​ Expected life (in years) 5.0 ​ Risk-free interest rate 1.7 % Dividend yield — % Expected volatility 132 % ​ Stock-based compensation (benefit) expense for the three months ended March 31, 2023 and 2022 was $(10) thousand and $323 thousand, respectively. The stock-based compensation benefit for the three months ended March 31, 2023, was related to the reversal of expense due to stock option forfeitures and cancellations. As of March 31, 2023, there was approximately $1.3 million of total unrecognized compensation cost related to 10,040 unvested stock options that is expected to be recognized over a weighted-average remaining vesting period of 3.2 years. ​ Warrants The following table details warrant activity for the three months ended March 31, 2023: ​ ​ ​ ​ ​ Number of Warrants outstanding Balance at December 31, 2021 197,000 Debenture, warrants issued ​ 9,000 Balance at December 31, 2022 206,000 Warrants cancelled (9,830) Balance at March 31, 2023 196,170 ​ ​ ​ The following table summarizes warrants issued by transaction type: ​ ​ ​ ​ ​ Number of Warrants outstanding Convertible debt, warrants issued (Note 5) 9,841 Debenture, warrants issued (Note 5) ​ 13,750 Other warrants issued ​ 9,000 December 2020 equity financing warrants issued (1) ​ 163,579 Total warrant outstanding 196,170 ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) For a complete discussion of the warrants issued during December 2020, see Note 11 to the consolidated financial statement for the year ended December 31, 2021 as filed on Form 10-K on March 14, 2022.

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Mar. 31, 2023
LOSS PER SHARE
LOSS PER SHARE	7. LOSS PER SHARE The following table sets forth the computation of basic and fully diluted loss per share for the three months ended March 31, 2023 and 2022 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Net loss $ (4,314) ​ $ (2,459) Basic weighted average common stock outstanding 1,054,933 ​ 645,950 Basic loss per share $ (4.09) ​ $ (3.81) Net loss $ (4,314) ​ $ (2,459) Dilutive weighted average common stock outstanding 1,054,933 ​ 645,950 Diluted loss per share $ (4.09) ​ $ (3.81) ​ Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the treasury stock method to calculate the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential dilutive common shares include incremental common shares issuable upon the exercise of stock options, less shares from assumed proceeds. The assumed proceeds calculation includes actual proceeds to be received from the employee upon exercise and the average unrecognized stock compensation cost during the period. Stock options to purchase 44,900 and 65,890 shares of common stock and warrants to purchase 196,170 and 197,000 shares of common stock were outstanding at March 31, 2023 and 2022 that were not included in the computation of diluted weighted average common stock outstanding because their effect would have been anti-dilutive.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
COMMITMENTS AND CONTINGENCIES.
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Indemnifications The Company is a party to a variety of agreements in the ordinary course of business under which it may be obligated to indemnify third parties with respect to certain matters. These obligations include, but are not limited to, contracts entered into with physicians where the Company agrees, under certain circumstances, to indemnify a third party, against losses arising from matters including but not limited to medical malpractice and other liability. The impact of any such future claims, if made, on future financial results is not subject to reasonable estimation because considerable uncertainty exists as to final outcome of these potential claims. As permitted under Nevada law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company believes, given the absence of any such payments in the Company’s history, and the estimated low probability of such payments in the future, that the estimated fair value of these indemnification agreements is immaterial. In addition, the Company has directors’ and officers’ liability insurance coverage that is intended to reduce its financial exposure and may enable the Company to recover any payments, should they occur. In April 2022, the U.S. Department of Justice (“DOJ)” issued Civil Investigative Demands which seek information with respect to a civil investigation under the Anti-kickback Statute and the False Claims Act. The Company voluntarily contacted the DOJ offering to provide any materials needed in the investigation and to answer any questions. While the Company’s policy during the relevant time was to not seek payments from federal health care programs, the third-party billing company utilized at that time submitted some claims to Medicare Advantage plans administered by commercial insurance companies. The Company has worked diligently to ensure that payments from Medicare Advantage plans have been returned to the commercial insurance companies and believes it has returned substantially all such payments that it has discovered to date, totaling approximately $450 thousand. The DOJ has not made any allegations in the investigation, and the Company is currently unable to predict the eventual scope, ultimate timing, or outcome of this investigation. As a result, the Company is unable to estimate the amount or range of any potential loss, if any, arising from this investigation. ​

SUBSEQUENT EVENT

SUBSEQUENT EVENT	3 Months Ended
	Mar. 31, 2023
SUBSEQUENT EVENT.
SUBSEQUENT EVENT	9. SUBSEQUENT EVENT ​ On May 12, 2023, the Company announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock (or prefunded warrants in lieu thereof) at an offering price to the public of $1.20 per share (or $1.199 per pre-funded warrant). The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.001 or on a cashless basis and may be exercised at any time until all of the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about May 16, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately $6 million, before deducting the underwriters’ fees and other offering expenses payable by Assure. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital, marketing, product development and capital expenditures. The Company has granted the underwriters in the offering a 45-day option to purchase up to 750,000 additional shares of the Company’s common stock and/or pre-funded warrants, in any combination thereof, from the Company at the public offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any. The securities were offered pursuant to the Company’s registration statement on Form S-1 (File No. 333-269438), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on May 11, 2023. th ​

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, and majority-owned entities. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. For entities in which management has determined the Company does not have a controlling financial interest but has varying degrees of influence regarding operating policies of that entity, the Company’s investment is accounted for using the equity method of accounting. All significant intercompany balances and transactions have been eliminated in consolidation.
Liquidity	Liquidity The Company’s current cash balance and estimated cash from operations for the next 12 months is not sufficient to meet the Company’s working capital needs for the next 12 months. The Company intends to seek equity or debt financing and have implemented significant cost cutting measures to mitigate its going concern. Such financings may include the issuance of shares of common stock, warrants to purchase common stock, convertible debt or other instruments that may dilute our current stockholders. Financing may not be available to us on acceptable terms depending on market conditions at the time we seek financing. however, there is no guarantee when, or if, these funds will be received during 2023.
Accounting Policies	Accounting Policies There have been no changes to the Company’s significant accounting policies or recent accounting pronouncements during the three months ended March 31, 2023, as compared to the significant accounting policies disclosed in the 10-K for the year ended December 31, 2022 as filed on March 31, 2023. On January 1, 2023, the Company adopted Accounting Standards Update No, 2016-13, and its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired, and each subsequent reporting period. The adoption of this standard did not have a material impact to the Company’s 2023 financial statements.
Common Stock Reverse Split	Common Stock Reverse Split During March 2023, the Company effectuated a twenty
Reclassifications	Reclassifications ​ Certain amounts for the three months ended March 31, 2022 have been reclassified to conform to the 2023 presentation.

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2023
REVENUE
Schedule of revenue disaggregated by payor	The Company’s revenue disaggregated by payor is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 ​ ​ ​ Commercial insurance $ 1,796 ​ $ 2,824 Facility billing ​ 1,312 ​ ​ 1,045 Managed service agreements and other ​ 444 ​ ​ 832 Total $ 3,552 ​ $ 4,701 ​
Summary of accounts receivable activity	A summary of the accounts receivable, net, by revenue stream is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ December 31, ​ 2023 2022 ​ ​ ​ ​ ​ ​ ​ Technical service ​ $ 2,614 $ 3,072 Professional service ​ ​ 10,067 ​ ​ 11,829 Other ​ 206 ​ 242 Total accounts receivable, net ​ $ 12,887 ​ $ 15,143 ​
Schedule of concentration of accounts receivable by revenue stream as a percentage of total accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, ​ As of December 31, ​ ​ 2023 2022 ​ ​ ​ ​ ​ Commercial insurance ​ 88 % ​ 84 % Facility billing ​ 8 % ​ 9 % Other ​ 4 % ​ 7 % Total 100 % ​ 100 %

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2023
LEASES
Schedule of right of use assets	The condensed consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of March 31, 2023 and December 31, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ December 31, ​ ​ 2023 2022 Operating $ 617 $ 672 Finance ​ 305 ​ 382 Total $ 922 $ 1,054 ​
Schedule of components of lease cost	The following are the components of lease cost for operating and finance leases (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2023 2022 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ $ 77 ​ $ 77 Interest on lease liabilities ​ ​ 19 ​ ​ 23 Total operating lease cost ​ ​ 96 ​ ​ 100 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 77 ​ ​ 169 Interest on lease liabilities ​ ​ 14 ​ ​ 24 Total finance lease cost ​ ​ 91 ​ ​ 193 Total lease cost ​ $ 187 ​ $ 293 ​
Schedule of weighted average lease terms and discount rates for operating and finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ ​ March 31, 2023 ​ March 31, 2022 ​ Weighted average remaining lease term (years): ​ ​ ​ ​ ​ Operating leases 2.5 ​ 3.5 ​ Finance leases 1.9 ​ 2.9 ​ Weighted average discount rate (%): ​ ​ ​ ​ ​ Operating leases 5.6 ​ 10.0 ​ Finance leases 9.2 ​ 7.8 ​ ​
Schedule of future minimum lease payments and related lease liabilities of financing leases	Future minimum lease payments and related lease liabilities as of March 31, 2023 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder of 2023 ​ $ 219 ​ $ 247 ​ $ 466 2024 ​ 328 ​ 268 ​ 596 2025 ​ 279 ​ 153 ​ 432 2026 ​ ​ — ​ ​ 23 ​ ​ 23 Total lease payments ​ 826 ​ 691 ​ 1,517 Less: imputed interest ​ (104) ​ (63) ​ (167) Present value of lease liabilities ​ ​ 722 ​ ​ 628 ​ ​ 1,350 Less: current portion of lease liabilities ​ 243 ​ 281 ​ 524 Noncurrent lease liabilities ​ $ 479 ​ $ 347 ​ $ 826 ​

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2023
DEBT
Summary of debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2023 2022 Face value of convertible debenture ​ $ 3,450 ​ $ 3,450 Less: principal converted to common shares ​ ​ (60) ​ ​ (60) Less: deemed fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 1,181 ​ ​ 1,086 Total convertible debt ​ 3,048 ​ 2,953 ​ ​ ​ ​ ​ ​ ​ Face value of Centurion debenture ​ ​ 11,000 ​ ​ 11,000 Less: deemed fair value ascribed to warrants ​ ​ (1,204) ​ ​ (1,204) Plus: accretion of implied interest ​ ​ 552 ​ ​ 476 Less: net debt issuance costs ​ ​ (347) ​ ​ (386) Total Centurion debt ​ 10,001 ​ 9,886 Total debt ​ 13,049 ​ 12,839 Less: current portion of debt ​ (2,620) ​ (965) Long-term debt ​ $ 10,429 ​ $ 11,874 ​
Schedule of accretion expense and interest expense related to debt obligations	The following table depicts accretion expense and interest expense (excluding debt issuance cost amortization) related to the Company’s debt obligations for the three months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Accretion expense ​ ​ Convertible debenture $ 95 ​ $ 95 Centurion debenture 75 ​ ​ 75 ​ $ 170 ​ $ 170 ​ ​ ​ ​ ​ ​ Debt issuance cost amortization ​ ​ Centurion debenture $ 39 ​ $ 40 ​ ​ ​ ​ ​ ​ Interest paid ​ ​ ​ ​ ​ Convertible debenture $ 174 ​ $ 77 Centurion debenture 376 ​ 263 ​ $ 550 ​ $ 340 ​
Schedule of future minimum principal payments	As of March 31, 2023, future minimum principal payments are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ Debt Debenture 2023 ​ $ 2,560 ​ $ — 2024 ​ 830 ​ — 2025 ​ — ​ 11,000 Total ​ ​ 3,390 ​ ​ 11,000 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,204) Plus: accretion and implied interest ​ 1,181 ​ 552 Less: net debt issuance costs ​ ​ — ​ ​ (347) ​ ​ $ 3,048 ​ $ 10,001 ​

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Mar. 31, 2023
SHARE CAPITAL
Schedule of stock options activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2021 60,212 ​ $ 111.20 3.60 ​ Options granted 6,500 ​ $ 103.20 ​ ​ ​ ​ ​ Options exercised (40) ​ $ 100.80 ​ ​ ​ ​ ​ Options canceled / expired (17,632) ​ $ 50.20 ​ ​ ​ ​ ​ Balance at December 31, 2022 49,040 ​ $ 129.60 ​ 2.8 ​ ​ ​ Options canceled / expired (4,100) ​ $ 112.72 ​ ​ ​ ​ ​ Balance at March 31, 2023 44,940 ​ $ 131.09 2.4 $ — Vested and exercisable at March 31, 2023 34,900 ​ $ 134.36 2.2 $ — ​
Schedule of stock options outstanding and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 750 4.8 ​ $ 180.00 750 ​ $ 180.00 4,200 0.5 ​ $ 180.00 4,200 ​ $ 180.00 7,290 0.8 ​ $ 156.00 7,290 ​ $ 156.00 3,395 1.5 ​ $ 128.00 3,395 ​ $ 128.00 3,900 2.7 ​ $ 97.00 2,860 ​ $ 97.00 12,255 ​ 2.8 ​ $ 106.00 ​ 9,174 ​ $ 106.00 1,500 ​ 3.0 ​ $ 112.00 ​ 900 ​ $ 112.00 7,650 ​ 3.5 ​ $ 153.00 ​ 4,465 ​ $ 153.00 4,000 ​ 3.9 ​ $ 103.20 ​ 1,866 ​ $ 103.20 44,940 2.4 ​ $ 131.09 34,900 ​ $ 134.36 ​
Schedule of assumptions were used to determine fair value of the awards	​ ​ ​ ​ ​ Expected life (in years) 5.0 ​ Risk-free interest rate 1.7 % Dividend yield — % Expected volatility 132 % ​
Schedule of warrants	​ ​ ​ ​ ​ Number of Warrants outstanding Balance at December 31, 2021 197,000 Debenture, warrants issued ​ 9,000 Balance at December 31, 2022 206,000 Warrants cancelled (9,830) Balance at March 31, 2023 196,170 ​ ​ ​ ​ ​ ​ Number of Warrants outstanding Convertible debt, warrants issued (Note 5) 9,841 Debenture, warrants issued (Note 5) ​ 13,750 Other warrants issued ​ 9,000 December 2020 equity financing warrants issued (1) ​ 163,579 Total warrant outstanding 196,170 ​

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2023
LOSS PER SHARE
Schedule of computation of basic and fully diluted (loss) income per common share	The following table sets forth the computation of basic and fully diluted loss per share for the three months ended March 31, 2023 and 2022 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Net loss $ (4,314) ​ $ (2,459) Basic weighted average common stock outstanding 1,054,933 ​ 645,950 Basic loss per share $ (4.09) ​ $ (3.81) Net loss $ (4,314) ​ $ (2,459) Dilutive weighted average common stock outstanding 1,054,933 ​ 645,950 Diluted loss per share $ (4.09) ​ $ (3.81) ​

NATURE OF OPERATIONS - Narrativ

NATURE OF OPERATIONS - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 subsidiary
NATURE OF OPERATIONS
Number of indirect wholly-owned subsidiaries	2

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	1 Months Ended	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2023
BASIS OF PRESENTATION
Stockholders' Equity, Reverse Stock Split		During March 2023, the Company effectuated a twenty -for-one reverse stock split. All share, stock option and warrant information has been retroactively adjusted to reflect the stock split. See Note 6 for additional discussion.
Reverse stock split ratio	0.05

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 3,552	$ 4,701
Commercial insurance
Disaggregation of Revenue [Line Items]
Total revenue	1,796	2,824
Facility billing
Disaggregation of Revenue [Line Items]
Total revenue	1,312	1,045
Managed service agreements and other
Disaggregation of Revenue [Line Items]
Total revenue	$ 444	$ 832

REVENUE - Accounts Receivable (

REVENUE - Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable, net:
Total accounts receivable, net	$ 12,887	$ 15,143
Technical services
Accounts receivable, net:
Total accounts receivable, net	2,614	3,072
Professional services
Accounts receivable, net:
Total accounts receivable, net	10,067	11,829
Other
Accounts receivable, net:
Total accounts receivable, net	$ 206	$ 242

REVENUE - Concentration of Acco

REVENUE - Concentration of Accounts Receivable (Details) - Accounts Receivable - Revenue Stream Concentration Risk	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	100%	100%
Commercial insurance
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	88%	84%
Facility billing
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	8%	9%
Other
Disaggregation of Revenue [Line Items]
Concentration of accounts receivable	4%	7%

LEASES - (Details)

LEASES - (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Incremental borrowing rate for operating lease	10%
Operating lease right of use asset, net	$ 617	$ 672
Finance lease right of use asset, net	305	382
Total right of use asset	922	1,054
Accumulated amortization of finance lease assets	$ 2,500	$ 2,400
Minimum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	5.20%
Maximum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	13.40%

LEASES - Components of Lease Co

LEASES - Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lease cost:
Amortization of ROU assets	$ 77	$ 77
Interest on lease liabilities	19	23
Total Operating lease cost	96	100
Amortization of ROU assets	77	169
Interest on lease liabilities	14	24
Total finance lease cost	91	193
Total lease cost	$ 187	$ 293

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details)	Mar. 31, 2023	Mar. 31, 2022
LEASES
Weighted average remaining lease term: Operating leases (in years)	2 years 6 months	3 years 6 months
Weighted average remaining lease term: Financing leases (in years)	1 year 10 months 24 days	2 years 10 months 24 days
Weighted average discount rate: Operating leases (as a percent)	5.60%	10%
Weighted average discount rate: Financing leases (as a percent)	9.20%	7.80%

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating Leases
Remainder of 2023	$ 219
2024	328
2025	279
Total lease payments	826
Less: imputed interest	(104)
Present value of lease liabilities	722
Less: current portion of lease liabilities	243
Noncurrent lease liabilities	479
Finance Leases
Remainder of 2023	247
2024	268
2025	153
2026	23
Total lease payments	691
Less: imputed interest	(63)
Present value of lease liabilities	628
Less: current portion of lease liabilities	281
Noncurrent lease liabilities	347
Total Lease Liabilities
Remainder of 2023	466
2024	596
2025	432
2026	23
Total lease payments	1,517
Less: imputed interest	(167)
Present value of lease liabilities	1,350
Less: current portion of lease liabilities	524
Noncurrent lease liabilities	$ 826

DEBT - Debt Obligations (Detail

DEBT - Debt Obligations (Details) - USD ($)	1 Months Ended
	Jun. 30, 2021	Mar. 31, 2023	Dec. 31, 2022	Jan. 31, 2022	Mar. 31, 2021
Debt
Total debt		$ 13,049,000	$ 12,839,000
Less: current portion of debt		(2,620,000)	(965,000)
Long-term debt		10,429,000	11,874,000
Paycheck Protection Program loan
Debt
Total				$ 0
Face amount					$ 1,700,000
Bearing interest rate					1%
Convertible Debt
Debt
Total		3,390,000
Face amount		3,450,000	3,450,000
Less: principal converted to common shares		(60,000)	(60,000)
Less: fair value ascribed to conversion feature and warrants		(1,523,000)	(1,523,000)
Plus: accretion of implied interest		1,181,000	1,086,000
Total debt		3,048,000	2,953,000
Centurion debenture
Debt
Face amount		11,000,000	11,000,000
Less: fair value ascribed to conversion feature and warrants		(1,204,000)	(1,204,000)
Plus: accretion of implied interest		552,000	476,000
Less: net debt issuance costs		(347,000)	(386,000)
Total debt		$ 10,001,000	$ 9,886,000
Debenture with Maturity Date of June 9, 2025 | Credit Facility dated March 8, 2021
Debt
Bearing interest rate	9.50%
Royal Bank of Canada Prime Rate | Debenture with Maturity Date of June 9, 2025 | Credit Facility dated March 8, 2021
Debt
Variable rate	7.05%
Centurion Debt | Credit Facility dated March 8, 2021
Debt
Face amount	$ 8,000,000
Fair value of debt	$ 6,800,000
Term of debt	4 years
Debt Instrument, Covenant Compliance	Under the terms and conditions of the debt arrangement, Centurion modified their debt covenant calculations to allow bad debt expense to be excluded.  The Company’s was in compliance with the debt covenants as of March 31, 2023.
Centurion Debt | Senior Term Loan
Debt
Maximum borrowing capacity	$ 6,000,000
Number of warrants issued	13,750
Warrant exercise price (in dollars per share)	$ 7.55
Centurion Debt | Senior Revolving Loan
Debt
Maximum borrowing capacity	$ 2,000,000
Centurion Debt | Senior Term Acquisition Line
Debt
Maximum borrowing capacity	3,000,000
Centurion Debt | Debenture with Maturity Date of June 9, 2025
Debt
Face amount	11,000,000
Centurion Debt | Warrants | Credit Facility dated March 8, 2021
Debt
Fair value of debt	$ 1,200,000

DEBT - Future Minimum Principal

DEBT - Future Minimum Principal Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt	$ 13,049	$ 12,839
Convertible Debt
Debt Instrument [Line Items]
2023	2,560
2024	830
Total	3,390
Less: fair value ascribed to conversion feature and warrants	(1,523)	(1,523)
Plus: accretion of implied interest	1,181	1,086
Total debt	3,048	$ 2,953
Debenture
Debt Instrument [Line Items]
2025	11,000
Total	11,000
Less: fair value ascribed to conversion feature and warrants	(1,204)
Plus: accretion of implied interest	552
Less: net debt issuance costs	(347)
Total debt	$ 10,001

DEBT - Accretion and interest e

DEBT - Accretion and interest expense, excluding debt issuance cost amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Debt Instrument [Line Items]
Accretion expense	$ 170	$ 170
Debt issuance cost amortization	39	40
Interest paid	550	340
Convertible Debt
Debt Instrument [Line Items]
Accretion expense	95	95
Interest paid	174	77
Centurion debenture
Debt Instrument [Line Items]
Accretion expense	75	75
Debt issuance cost amortization	39	40
Interest paid	$ 376	$ 263

DEBT - Additional Information (

DEBT - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		14 Months Ended
	Jan. 31, 2022	May 31, 2020	Dec. 31, 2020	Mar. 31, 2021
Non-brokered private placements of convertible debenture units ("CD Unit")
Debt
Proceeds from convertible debenture		$ 3,500	$ 3,500
Conversion price (in dollars per share)			$ 1
Interest rate			9%
Fair value of debt		1,700
Conversion feature		$ 1,200
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche
Debt
Term of debt			3 years
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche | Minimum
Debt
Conversion price (in dollars per share)			$ 5
Non-brokered private placements of convertible debenture units ("CD Unit") | First tranche | Maximum
Debt
Conversion price (in dollars per share)			$ 9.50
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche
Debt
Term of debt		4 years	4 years
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche | Minimum
Debt
Conversion price (in dollars per share)			$ 3.35
Non-brokered private placements of convertible debenture units ("CD Unit") | Second tranche | Maximum
Debt
Conversion price (in dollars per share)			$ 7
Non-brokered private placements of convertible debenture units ("CD Unit") | Warrants
Debt
Fair value of debt		$ 600
Paycheck Protection Program loan
Debt
Interest rate				1%
Debt forgiveness	$ 1,700

SHARE CAPITAL - Narrative (Deta

SHARE CAPITAL - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 $ / shares shares	Sep. 30, 2022 shares
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common stock, shares authorized	9,000,000	9,000,000	9,000,000	180,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued	1,101,098	1,101,098	1,051,098
Common stock, shares outstanding	1,101,098	1,101,098	1,051,098
Common stock authorized after Reverse Share Split (shares)	9,000,000
Reverse stock split ratio	0.05
Fractional shares issued	0
Gross proceeds | $		$ 300
Amended Stock Option Plan
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common stock, shares outstanding	40,940	40,940
Equity Incentive Plan
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common stock, shares outstanding	4,000	4,000
Number of shares authorized	96,000	96,000
Private Placements
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Shares issued	50,000
Shares issue price | $ / shares	$ 6	$ 6
Gross proceeds | $	$ 300

SHARE CAPITAL - Stock Options (

SHARE CAPITAL - Stock Options (Details) - Stock options - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options at beginning of period (in shares)	49,040	60,212
Options granted (in shares)		6,500
Options exercised (in shares)		(40)
Options canceled / expired (in shares)	(4,100)	(17,632)
Options at end of period (in shares)	44,940	49,040	60,212
Options vested and exercisable as at end of the period	34,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercise Price at beginning of period (in dollars per share)	$ 129.60	$ 111.20
Options granted (in dollars per share)		103.20
Options exercised (in dollars per share)		100.80
Options canceled / expired (in dollars per share)	112.72	50.20
Exercise Price at end of period (in dollars per share)	131.09	$ 129.60	$ 111.20
Exercise Price vested and exercisable (in dollars per share)	$ 134.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life (in years)	2 years 4 months 24 days	2 years 9 months 18 days	3 years 7 months 6 days
Weighted Average Remaining life vested and exercisable (in years)	2 years 2 months 12 days

SHARE CAPITAL - Stock Options O

SHARE CAPITAL - Stock Options Outstanding and Exercisable (Details) - Stock options - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	44,940	49,040	60,212
Weighted Average Remaining Contractual Life (in years)	2 years 4 months 24 days	2 years 9 months 18 days	3 years 7 months 6 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 131.09	$ 129.60	$ 111.20
Number Exercisable (in shares)	34,900
Weighted average exercise price of options exercisable (in dollars per share)	$ 134.36
$180.00 Exercise Price Per Share, group one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	750
Weighted Average Remaining Contractual Life (in years)	4 years 9 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 180
Number Exercisable (in shares)	750
Weighted average exercise price of options exercisable (in dollars per share)	$ 180
$180.00 Exercise Price Per Share, group two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	4,200
Weighted Average Remaining Contractual Life (in years)	6 months
Weighted average exercise price of options outstanding (in dollars per share)	$ 180
Number Exercisable (in shares)	4,200
Weighted average exercise price of options exercisable (in dollars per share)	$ 180
$156.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	7,290
Weighted Average Remaining Contractual Life (in years)	9 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 156
Number Exercisable (in shares)	7,290
Weighted average exercise price of options exercisable (in dollars per share)	$ 156
$128..00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	3,395
Weighted Average Remaining Contractual Life (in years)	1 year 6 months
Weighted average exercise price of options outstanding (in dollars per share)	$ 128
Number Exercisable (in shares)	3,395
Weighted average exercise price of options exercisable (in dollars per share)	$ 128
$97.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	3,900
Weighted Average Remaining Contractual Life (in years)	2 years 8 months 12 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 97
Number Exercisable (in shares)	2,860
Weighted average exercise price of options exercisable (in dollars per share)	$ 97
$106.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	12,255
Weighted Average Remaining Contractual Life (in years)	2 years 9 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 106
Number Exercisable (in shares)	9,174
Weighted average exercise price of options exercisable (in dollars per share)	$ 106
$112.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	1,500
Weighted Average Remaining Contractual Life (in years)	3 years
Weighted average exercise price of options outstanding (in dollars per share)	$ 112
Number Exercisable (in shares)	900
Weighted average exercise price of options exercisable (in dollars per share)	$ 112
$153.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	7,650
Weighted Average Remaining Contractual Life (in years)	3 years 6 months
Weighted average exercise price of options outstanding (in dollars per share)	$ 153
Number Exercisable (in shares)	4,465
Weighted average exercise price of options exercisable (in dollars per share)	$ 153
$103.20.00 Exercise Price Per Share
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	4,000
Weighted Average Remaining Contractual Life (in years)	3 years 10 months 24 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 103.20
Number Exercisable (in shares)	1,866
Weighted average exercise price of options exercisable (in dollars per share)	$ 103.20

SHARE CAPITAL - Assumptions Use

SHARE CAPITAL - Assumptions Used (Details)	3 Months Ended
	Mar. 31, 2022
SHARE CAPITAL
Expected life (in years)	5 years
Risk-free interest rate	1.70%
Expected volatility	132%

SHARE CAPITAL - Stock-based Com

SHARE CAPITAL - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
SHARE CAPITAL
Stock-based compensation expense recognized	$ (10)	$ 323
Unrecognized compensation cost	$ 1,300
Unvested stock options (in shares)	10,040
Weighted-average remaining vesting period	3 years 2 months 12 days

SHARE CAPITAL - Warrants (Detai

SHARE CAPITAL - Warrants (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Number of warrants outstanding	196,170	206,000	197,000
Debenture, warrants issued		9,000
Warrants cancelled	(9,830)
Convertible Debt
Class of Warrant or Right [Line Items]
Number of warrants outstanding	9,841
Centurion debenture
Class of Warrant or Right [Line Items]
Number of warrants outstanding	13,750
Other warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding	9,000
December 2020 equity financing
Class of Warrant or Right [Line Items]
Number of warrants outstanding	163,579

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss	$ (4,314)	$ (2,459)
Basic weighted average common stock outstanding	1,054,933	645,950
Basic loss per share	$ (4.09)	$ (3.81)
Dilutive weighted average common stock outstanding	1,054,933	645,950
Diluted loss per share	$ (4.09)	$ (3.81)
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average common shares	44,900	65,890
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average common shares	196,170	197,000

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands	Apr. 30, 2022 USD ($)
Indemnification Agreement
Commitments and Contingencies
Contingent liability	$ 450

SUBSEQUENT EVENT (Details)

SUBSEQUENT EVENT (Details) - Subsequent Events $ / shares in Units, $ in Millions	May 12, 2023 USD ($) $ / shares shares
Subsequent Event [Line Items]
Underwritten public offering, number of shares | shares	5,000,000
Price per share	$ 1.20
Warrant exercise price (in dollars per share)	$ 0.001
Expected gross proceeds to the Company from the offering | $	$ 6
Note Warrant [Member]
Subsequent Event [Line Items]
Price per share	$ 1.199
Over-Allotment Option [Member]
Subsequent Event [Line Items]
Underwritten public offering, number of shares | shares	750,000
Option period	45-day